Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • US FDA issues draft...

    US FDA issues draft norms for difluprednate, an ophthalmic emulsion to treat eye swelling and pain

    Written by supriya kashyap kashyap Published On 2017-02-28T09:10:22+05:30  |  Updated On 28 Feb 2017 9:10 AM IST
    US FDA issues draft norms for difluprednate, an ophthalmic emulsion to treat eye swelling and pain

    Bengaluru : The USFDA has issued a draft guidance for the active ingredient difluprednate which is an ophthalmic emulsion with a strength of 0.05 per cent. The drug is categorised under corticosteroids and works to stall the release of certain natural substances that cause swelling and pain. The drug which is used for eye surgery has the regulatory authority insisting on data of a comparative study which should be performed on at least three exhibit lots of both test and reference products.


    In order to determine the strength of the product, the regulator has recommended two options: in vitro or in vivo study. Firstly, the manufacturer will need to qualify for the in vitro option for this drug product. It should ensure that the test and Reference Listed Drug (RLD) formulations are qualitatively and quantitatively the same.


    Secondly, it is the acceptable comparative physicochemical characterization of the test and RLD formulations. The comparative study needs to be conducted of both test and reference products.


    The regulator has also fixed parameters to measure the globule size distribution, viscosity profile as a function of applied shear, pH, zeta potential, osmolality, and surface tension. Sponsors should also submit information on the drug distribution in different phases within the formulation.


    Population bioequivalence (PBE) is recommended in the case of globule size distribution. The other parameters do not require PBE analysis. The applicants should provide not less than 10 data sets from 3 batches with each of the test and reference products to be used in the PBE analysis. Sponsors should compare the size parameter upon serial dilution of the test and reference products, and provide histograms of size distribution data of each diluted sample, stated the regulatory note.


    Under in-vivo option, the regulator recommends one bioequivalence study with pharmacokinetic (PK) endpoint. The subjects for this study should be patients undergoing indicated cataract surgery. In addition, the regulator calls to submit metabolite data as supportive evidence of therapeutic outcome.


    According to the government ophthalmic care majors like Minto Eye Hospital, affiliated to the Bangalore Medical College and Research Institute, the drug difluprednate is a corticosteroid and is approved for the treatment of post-operative ocular inflammation and pain. “There are efforts to extend its use for other ocular inflammatory diseases which are on the rise. Therefore, there is need for constant update on clinical efficacy and adverse drug reactions.”

    Corticosteroidsdifluprednateeye swelling and painophthalmicPopulation bioequivalenceReference Listed Drugswelling
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok